Employers drop coverage for weight loss drugs as pharma’s direct-to-consumer programs grow – statnews.com
Employers drop coverage for weight loss drugs as pharma’s direct-to-consumer programs grow statnews.com Opinion | How to cut the velvet rope to GLP-1s The Washington Post Obesity recognition ‘going in right direction’ amid GLP-1 revolution, but obstacles remain thehill.com Covering the High Cost of Weight Loss Drugs National Conference of State Legislatures (NCSL) Study finds 40% of GLP-1 prescriptions […]
Eli Lilly’s Experimental Pill Could Help You Ditch GLP-1 Obesity Shots, Trial Finds
People who switched from semaglutide or tirzepatide to orforglipron largely maintained their weight loss.
Orforglipron Helps Maintain Weight Loss After Injectables
Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people maintain weight loss after switching from an injectable. Medscape Medical News
Eli Lilly is eyeing an off-ramp for patients to switch from weight loss injections to pills
Although the injectable forms of the popular GLP-1 drugs are more effective, the pills under development are both easier to take and will be cheaper
Can you get addicted to a GLP-1?
Model Brooks Nader calls these drugs a “crutch.”
Neovascular Age-Related Macular Degeneration and GLP-1 RAs—Reply
In Reply We read the letters with great interest commenting on our recent article. We agree that surveillance bias is a concern in observational studies using administrative data. To mitigate this, we implemented several methodological approaches. First, we used duration of diabetes as a covariate in propensity score matching, which serves as a proxy for […]
Rise of Direct-to-Patient GLP-1 Sales Shakes Up Care Models, HCPs Split on Pharma’s Expanding Role
NEW YORK–(BUSINESS WIRE)–The 43rd Barometer from Sermo, a fast, frictionless HCP social engagement platform and leader in healthcare insights, shows that pharma-led direct-to-patient (DTP) GLP-1 prescribing programs are transforming treatment access pathways. Yet findings from 953 surveyed GLP-1 prescribers reveal sharp divisions over how involved pharma should be in clinical evaluation and prescribing. DTP Models […]
More GLP-1s aim to enter US market
Novo Nordisk is seeking FDA approval for an experimental obesity shot, CagriSema (cagrilintide and semaglutide), according to a Dec. 18 news release from the Denmark-based drugmaker. CagriSema is a weekly injection of semaglutide, a GLP-1, and cagrilintide, a long-acting amylin analogue. If approved, the drug would be the first injectable GLP-1 and amylin analogue combination […]
Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share?
Novo Nordisk NVO is a leading player in the obesity market, driven by its blockbuster GLP-1 therapy Wegovy (semaglutide). However, despite being a core growth driver, Wegovy’s sales momentum has slowed in recent quarters. The deceleration is primarily attributed to intensifying competition in the GLP-1 space, most notably from its arch-rival Eli Lilly LLY, as well […]
STAT+: Pharmalittle: We’re reading about Lilly’s obesity pill, pharma deals with Trump, and much more
Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are enveloping the Pharmalot campus, where the official mascots are foraging for noshes and keeping strangers at bay. As for us, we are engaged in the usual rituals, starting with firing up the coffee kettle — our […]